Media coverage about TG Therapeutics (NASDAQ:TGTX) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TG Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.1226747999687 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s scoring:
- TG Therapeutics, Inc. (NASDAQ:TGTX) – Hot Mover to Watch – Nasdaq Journal (press release) (nasdaqjournal.com)
- Trader’s Focus- TG Therapeutics, Inc. (TGTX) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- TG Therapeutics Inc (NASDAQ:TGTX) Reports Clinical And Preclinical Data Presentations – USMarketsDaily (blog) (usmarketsdaily.com)
- TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : December 20, 2017 (finance.yahoo.com)
- TG Therapeutics Inc (TGTX) Expected to Announce Quarterly Sales of $40,000.00 (americanbankingnews.com)
Several equities research analysts have recently commented on TGTX shares. HC Wainwright reissued a “buy” rating and issued a $33.00 target price (up from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. B. Riley assumed coverage on TG Therapeutics in a research note on Friday, December 1st. They set a “buy” rating and a $21.50 price objective for the company. ValuEngine cut TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. SunTrust Banks reaffirmed a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a research note on Tuesday, October 3rd. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.50.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. equities research analysts predict that TG Therapeutics will post -1.86 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/23/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-tg-therapeutics-tgtx-share-price.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.